Astron Pulsar; Pulsar-18; Pulsar-18 T3
Biotronik AG · Decision date Dec 17, 2025
What did the FDA decide?
FDA records P160025/S023 as a supplement to PMA P160025, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Dec 17, 2025.
FDA approval order statement
new hydrogen content testing equipment
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Dec 17, 2025
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P160025/S023
- Regulatory pathway
- PMA supplement
- Applicant
- Biotronik AG
- Product code
- NIP
- Decision code
- OK30
- Decision date
- Dec 17, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: STENT, SUPERFICIAL FEMORAL ARTERY.
- Applicant
- Biotronik AG
- Product code
- NIP
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P160025. Subsequent supplements may change the device or its indications.
FDA decision timeline
P160025 · Original PMA
ASTRON PULSAR STENT SYSTEM, PULSAR-18 STENT SYSTEM
P160025/S022 · Related supplement
Pulsar-18 T3 Stent System
P160025/S023 received
Application receipt date recorded by FDA.
P160025/S023 · FDA decision
30-Day Notice
P160025/S024 · Related supplement
Astron Pulsar Pulsar-18, Pulsar-18 T3
P160025/S025 · Related supplement
Pulsar-18 T3 Peripheral Self-Expanding Nitinol Stent System
P160025/S026 · Related supplement
Pulsar-18 T3 Peripheral Self-Expanding Nitinol Stent System
Timeline entries are records held by MedtechLedger for P160025. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P160025
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Biotronik AG | PMA approval | Mar 23, 2017 | FDA | |
Pulsar-18 T3 Stent SystemP160025/S022 | Biotronik AG | PMA supplement | Oct 21, 2025 | FDA |
Astron Pulsar Pulsar-18, Pulsar-18 T3P160025/S024 | Biotronik AG | PMA supplement | Mar 10, 2026 | FDA |
| Biotronik AG | PMA supplement | Jun 22, 2026 | FDA | |
| Biotronik AG | PMA supplement | Sep 11, 2026 | FDA |
Explore the linked device profile
Other records with product code NIP
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Supera Peripheral Stent SystemP120020/S037 | Abbott Vascular (Idef Technologies Inc) | PMA supplement | Nov 6, 2026 | FDA |
| Medtronic Vascular, Inc. | PMA supplement | Nov 5, 2026 | FDA | |
| Medtronic Vascular, Inc. | PMA supplement | Oct 16, 2026 | FDA | |
| Cordis US Corporation | PMA supplement | Oct 15, 2026 | FDA | |
| BOSTON SCIENTIFIC CORPORATION | PMA supplement | Aug 21, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Biotronik AG
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Ackerstrasse 6, Bülach, 8180
Sources and methodology
- Original FDA record: P160025/S023
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




